Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy

To join this study, you would need to be an adult (18 years or older) with large B-cell lymphoma. This study is specifically for people whose cancer either hasn't responded well to their first treatment, or has come back after their first treatment, within 12 months. Your previous treatment must have included a specific type of antibody therapy (anti-CD20) and a chemotherapy drug called an anthracycline.

Your doctor will need to confirm that you have measurable signs of the lymphoma. This means there's a way to track the cancer's size and how it responds to treatment. There are also specific rules about how much time must have passed since your last treatment and if you've had any other treatments since your first main one. If you have another type of lymphoma that has changed into large B-cell lymphoma, the treatments you had for the original lymphoma might not count towards the eligibility.

It's important to know that these are just some of the main rules. There are other detailed criteria your doctor will check to make sure the study is right for you and safe for you to take part.

The detailed plan for taking part in this study would be explained by your study doctor. It would involve regular visits to the hospital or clinic for check-ups, tests, and to receive your assigned treatment (either KITE-753 or axicabtagene ciloleucel). You would also receive some chemotherapy drugs (Fludarabine and Cyclophosphamide) before the main treatment.

These visits might include blood tests, scans (like CT scans), and physical examinations to see how you are responding to the treatment and to monitor your general health. You would be closely monitored, especially after receiving the main treatment, to manage any side effects. The total duration of your participation, including follow-up, would be fully explained before you agree to join.